Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of risk factor burden and vascular bed involvement on dementia risk in individuals with established cardiovascular disease.

American journal of preventive cardiology·2026
Same author

Potential impact on cholesterol goal achievement and predicted cardiovascular risk by the addition of ezetimibe and bempedoic acid on top of statins: a simulation from the SANTORINI study.

American journal of preventive cardiology·2026
Same author

Predicting lifetime cardiovascular risk and benefits of preventive treatment in patients with established atherosclerotic cardiovascular disease: the SMART-REACH2 model.

European heart journal·2026
Same author

Comparison of different long-term cardiovascular disease risk prediction horizons to guide preventive drug treatment in apparently healthy individuals.

European heart journal. Quality of care & clinical outcomes·2026
Same author

Multinational validation of the PREVENT and SCORE2 cardiovascular risk equations across 6.4 million individuals.

Nature medicine·2026
Same author

An online, predominantly plant-based, dietary intervention for improving cardiovascular risk: A randomized controlled trial in people with type 2 diabetes.

American heart journal·2026

Related Experiment Video

Updated: Jun 3, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

[Muscle problems due to statins: underestimated].

Stan P Janssen1, Yvo M Smulders, Victor E Gerdes

  • 1Universitair Medisch Centrum Utrecht, Afd. Vasculaire Geneeskunde, The Netherlands. sp.janssen@mindef.nl

Nederlands Tijdschrift Voor Geneeskunde
|March 26, 2011
PubMed
Summary
This summary is machine-generated.

Statin-associated muscle problems affect about 10% of patients, often within six months. Lowering or stopping statin therapy is the primary treatment for these common side effects.

Related Experiment Videos

Last Updated: Jun 3, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Area of Science:

  • Pharmacology
  • Clinical Medicine

Context:

  • Statin-associated muscle problems (SAMPs) are frequently underestimated, with observational studies indicating a prevalence of approximately 10%, significantly higher than the 1-5% reported in major clinical trials.
  • These muscle issues can manifest at any point during statin therapy, though they most commonly appear within the initial six months of treatment.

Purpose:

  • To elucidate the prevalence, causes, risk factors, and management strategies for statin-associated muscle problems.
  • To differentiate between common myopathy and rare rhabdomyolysis in the context of statin use.

Summary:

  • The primary mechanism for statin-induced myopathy is likely the depletion of isoprenoids resulting from HMG-CoA reductase inhibition.
  • Key risk factors for SAMP include polypharmacy, alcohol abuse, hypothyroidism, and a genetic predisposition to statin-induced muscle issues.
  • Management involves addressing risk factors and, crucially, reducing the statin dosage or discontinuing the medication. Approximately 40% of patients may tolerate a different statin formulation.

Impact:

  • Highlights the higher real-world incidence of statin-induced muscle problems compared to clinical trial data.
  • Provides essential information for clinicians on identifying and managing SAMP, including risk factor mitigation and therapeutic adjustments.
  • Emphasizes that while rhabdomyolysis is rare, proactive management of myopathy is crucial for patient adherence and safety. The efficacy of supplements like CoQ10 remains unproven.